Nicholson Wealth Management Group LLC Boosts Stake in Becton, Dickinson and Company $BDX

Nicholson Wealth Management Group LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,433 shares of the medical instruments supplier’s stock after buying an additional 130 shares during the quarter. Nicholson Wealth Management Group LLC’s holdings in Becton, Dickinson and Company were worth $1,108,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Northcape Wealth Management LLC raised its position in Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock worth $2,248,000 after purchasing an additional 51 shares during the period. Brady Family Wealth LLC raised its position in Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock worth $989,000 after purchasing an additional 53 shares during the period. Diversified Trust Co raised its position in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 53 shares during the period. Bill Few Associates Inc. raised its position in Becton, Dickinson and Company by 0.7% in the 2nd quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 55 shares during the period. Finally, Horizon Bancorp Inc. IN raised its position in Becton, Dickinson and Company by 10.9% in the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 56 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 1,838 shares of company stock worth $348,392 in the last 90 days. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $189.20 on Friday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company’s 50-day moving average is $190.60 and its 200 day moving average is $184.92. The stock has a market capitalization of $54.23 billion, a P/E ratio of 34.03, a P/E/G ratio of 1.45 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.32 billion for the quarter. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Analysts Set New Price Targets

A number of equities analysts recently commented on BDX shares. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday. Morgan Stanley raised their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Finally, Argus raised their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.